US 12,076,328 B2
Pharmaceutical compositions of niclosamide
Robert O. Williams, III, Austin, TX (US); Hugh D. C. Smyth, Austin, TX (US); Zachary N. Warnken, Austin, TX (US); Miguel Orlando Jara Gonzalez, Austin, TX (US); Hyo-Jong Seo, Austin, TX (US); Ashlee D. Brunaugh, Austin, TX (US); and Matthew Herpin, Austin, TX (US)
Assigned to Board of Regents, The University of Texas System, Austin, TX (US)
Filed by BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, Austin, TX (US)
Filed on Apr. 1, 2021, as Appl. No. 17/220,833.
Claims priority of provisional application 63/003,793, filed on Apr. 1, 2020.
Prior Publication US 2021/0322445 A1, Oct. 21, 2021
Int. Cl. A61K 31/609 (2006.01); A61K 9/00 (2006.01); A61K 47/10 (2017.01); A61K 47/32 (2006.01); A61K 47/58 (2017.01)
CPC A61K 31/609 (2013.01) [A61K 9/0053 (2013.01); A61K 47/10 (2013.01); A61K 47/32 (2013.01); A61K 47/58 (2017.08)] 14 Claims
 
1. A pharmaceutical composition comprising:
(A) an active agent, wherein the active agent is niclosamide, a pharmaceutically acceptable salt thereof, a hydrate, or a co-crystal thereof; and
(B) a pharmaceutically acceptable polymer, wherein the pharmaceutically acceptable polymer is a copolymer of polyvinyl pyrrolidone and polyvinyl acetate; and
(C) a surfactant, wherein the surfactant is tocopheryl polyethylene glycol succinate;
wherein the pharmaceutical composition is formulated for oral administration and the active agent is present in the amorphous form and is phase separated in the pharmaceutical composition.